论文部分内容阅读
目的探讨外周血血管内皮抑素和血管抑素检测在胰腺癌患者病程判断中的意义。方法选取134例胰腺癌患者和50例健康对照,根据胰腺癌患者病情状况分为不可切除组(A组,n=56)和可切除组(B组,n=78),分别于胰腺癌患者入院后1d和可切除患者术后7 d,以及正常对照均抽取晨起空腹肘静脉血,采用酶联免疫吸附试验。ELISA)法对所有标本中血管内皮抑素和血管抑素含量进行检测。结果胰腺癌患者血清血管内皮抑素和血管抑素含量均高于对照组,差异均具有统计学意义(P<0.05)。A组患者术前血清血管内皮抑素和血管抑素含量均高于B组,B组患者术后7 d血清血管内皮抑素和血管抑素含量均低于术前,差异均具有统计学意义(P<0.05)。Pearson相关分析显示,胰腺癌患者血清血管内皮抑素含量与血管抑素含量呈正相关(r=0.530,P=0,000),Spearman相关分析显示,胰腺癌患者血清血管内皮抑素和血管抑素含量均与患者病程呈正相关(r=0.796和0.637,均P<0.05)。胰腺癌患者血清血管内皮抑素含量与肿瘤大小有关(P<0.05),血管抑素含量与肿瘤大小和血管侵犯有关(P<0.05)。结论胰腺癌患者血清血管内皮抑素和血管抑素含量均出现升高,且随病情进展含量升高,与肿瘤生长和血管侵袭密切相关。
Objective To investigate the significance of the detection of peripheral blood endostatin and angiostatin in the course of disease in patients with pancreatic cancer. Methods A total of 134 patients with pancreatic cancer and 50 healthy controls were selected and divided into unresectable group (group A, n = 56) and resectable group (group B, n = 78) according to the condition of the patients with pancreatic cancer On the first day after admission and resectable patients after 7 days, as well as the normal control were taken morning fasting elbow venous blood, using enzyme-linked immunosorbent assay. ELISA method for the determination of endostatin and angiostatin levels in all specimens. Results Serum levels of endostatin and angiostatin in patients with pancreatic cancer were significantly higher than those in control group (P <0.05). The serum levels of endostatin and angiostatin in group A were significantly higher than those in group B, and the levels of serum endostatin and angiostatin in group B were lower than those before operation (P <0.05). Pearson correlation analysis showed that there was a positive correlation between serum endostatin and angiostatin in patients with pancreatic cancer (r = 0.530, P = 0, 000). Spearman correlation analysis showed that serum endostatin and angiostatin contents in patients with pancreatic cancer And the patient’s course was positively correlated (r = 0.796 and 0.637, both P <0.05). Serum endostatin levels in patients with pancreatic cancer correlated with tumor size (P <0.05), and angiostatin levels correlated with tumor size and vascular invasion (P <0.05). Conclusions Serum levels of endostatin and angiostatin in patients with pancreatic cancer both increase, and with the progression of the disease, the levels of serum endostatin and angiostatin are closely related to tumor growth and vascular invasion.